This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Dermatol. 1999;135:1284-1285.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

SINCE LICENSURE of rubella vaccines in 1969, the incidence of rubella and congenital rubella syndrome (CRS) in the United States has decreased substantially. Rubella infection during the first trimester of pregnancy can result in miscarriage, stillbirth, or infants with a pattern of birth defects (i.e., CRS).¹ One of the national health objectives for 2000 is to eliminate indigenous rubella and CRS (objective 20.1).² During 1997-1998, 524 cases of rubella were reported in the United States (CDC, unpublished data, 1999). This report describes a rubella outbreak in Westchester County, New York, demonstrates the importance of accurately defining and vaccinating at-risk populations to prevent transmission, and underscores how collaboration with community-based organizations can facilitate the development and implementation of control measures.

During the outbreak, a clinical case of rubella was defined as an illness with an acute onset of generalized maculopapular rash, a temperature of >99 F ( >37.2 C), and arthralgia/arthritis, . . . [Full Text of this Article]

Reported by:


CDC Editorial Note: